BioNet is a French-Thai biotech organisation with more than 250 employees globally, fully dedicated to the development of recombinant and mRNA vaccines targeting respiratory diseases, re-emerging, and pandemic threats. With a proven track record in development and biomanufacturing, BioNet has successfully advanced three proprietary recombinant pertussis vaccines from early R&D to licensure. Through its well-established commercial network, the organisation currently markets a range of vaccines. BioNet is rapidly expanding its global presence, with operations spanning Asia, Europe, and North America.
Our Breakthroughs
Activities Leading Our Vision
3 proprietary recombinant
pertussis vaccines
1
Recombinant pertussis vaccine
2
Tetanus toxoid, reduced diphtheria toxoid, recombinant pertussis vaccine
3
Tetanus toxoid, reduced diphtheria toxoid, reduced recombinant pertussis vaccine
Publications
Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: Real-world evidence
Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines
A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in women of childbearing age
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial
Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand